ADiTx Therapeutics Inc.

0.1530+0.0070+4.79%Vol 7.68M1Y Perf -94.43%
Jun 24th, 2022 16:00 DELAYED
BID0.1511 ASK0.1600
Open0.1463 Previous Close0.1460
Pre-Market- After-Market0.15
 - -  0.00 -0.26%
Target Price
6.00 
Analyst Rating
Strong Buy 1.00
Potential %
3.82K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     28.70
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.75 
Earnings Rating
Market Cap6.84M 
Earnings Date
-
Alpha-0.10 Standard Deviation0.25
Beta0.71 

Today's Price Range

0.14000.1679

52W Range

0.12423.95

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
10.07%
1 Month
-40.70%
3 Months
-66.54%
6 Months
-78.45%
1 Year
-94.43%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADTX0.15300.00704.79
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.00
0.35
0.91
-26.60
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
15.60
-14 076.20
-13 915.30
-
-
RevenueValueIndustryS&P 500US Markets
315.31K
0.01
-
-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume7.68M
Shares Outstanding44.73K
Shares Float42.38M
Trades Count4.35K
Dollar Volume1.21M
Avg. Volume3.29M
Avg. Weekly Volume6.56M
Avg. Monthly Volume2.18M
Avg. Quarterly Volume1.11M

ADiTx Therapeutics Inc. (NASDAQ: ADTX) stock closed at 0.153 per share at the end of the most recent trading day (a 4.79% change compared to the prior day closing price) with a volume of 7.68M shares and market capitalization of 6.84M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. ADiTx Therapeutics Inc. CEO is Amro A. Albanna.

The one-year performance of ADiTx Therapeutics Inc. stock is -94.43%, while year-to-date (YTD) performance is -71.46%. ADTX stock has a five-year performance of %. Its 52-week range is between 0.1242 and 3.95, which gives ADTX stock a 52-week price range ratio of 0.75%

ADiTx Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 1.32, a price-to-sale (PS) ratio of 19.72, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -308.98%, a ROC of -340.56% and a ROE of -572.32%. The company’s profit margin is -%, its EBITDA margin is -13 915.30%, and its revenue ttm is $315.31 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from ADiTx Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ADiTx Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ADiTx Therapeutics Inc. is Strong Buy (1), with a target price of $6, which is +3 821.57% compared to the current price. The earnings rating for ADiTx Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADiTx Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADiTx Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.40, ATR14 : 0.04, CCI20 : -96.92, Chaikin Money Flow : -0.19, MACD : -0.04, Money Flow Index : 53.10, ROC : -45.97, RSI : 32.79, STOCH (14,3) : 12.75, STOCH RSI : 1.00, UO : 23.27, Williams %R : -87.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADiTx Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ADiTx Therapeutics Inc.

ADiTx Therapeutics Inc is a pre-clinical stage, life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

CEO: Amro A. Albanna

Telephone: +1 909 488-0844

Address: 11161 Anderson Street, Loma Linda 92354, CA, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

66%34%

Bearish Bullish

66%34%

News

Stocktwits